Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

Kelly L. Sullivan

Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

Kelly L. Sullivan

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Disciplines

Epidemiology
Public Health

Cite this

@misc{9e7b2e832fad4eaf90fe3a2485b5e0c2,

title = "Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix{\textregistered}) in the Treatment of Friedreich's Ataxia",

author = "Sullivan, \{Kelly L.\}",

note = "Kelly L. Sullivan (Epidemiologist \& Project Manager), {"}Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix{\textregistered}) in the Treatment of Friedreich's Ataxia,{"} Pfizer and Friedreich{\textquoteright}s Ataxia Research Alliance (Investigator Initiated). (2008-2011).",

year = "2008",

language = "American English",

type = "Other",

}

TY - GEN

T1 - Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

AU - Sullivan, Kelly L.

N1 - Kelly L. Sullivan (Epidemiologist & Project Manager), "Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia," Pfizer and Friedreich’s Ataxia Research Alliance (Investigator Initiated). (2008-2011).

PY - 2008

Y1 - 2008

M3 - Other

ER -